The drug class of SGLT-2-inhibitors were not included as antidiabetic nor HF therapy because patients were included into the registry in parallel to the publication of the EMPA-REG-OUTCOME trial [30] and prior to the updated guideline recommendation for antidiabetic treatment, 2018 [31]. The gene discussed is SLC5A2; the disease is hydrops fetalis.